Efficacy and tolerability of frovatriptan in acute migraine treatment: Systematic review of randomized controlled trials

Journal of Clinical Pharmacy and Therapeutics

Volumn 30, Issue 6, 2005, Pages 521-532

  Poolsup, N ^a   Leelasangaluk, V ^a   Jittangtrong, J ^a   Rithlamlert, C ^a   Ratanapantamanee, N ^a   Khanthong, M ^a  

^a SILPAKORN UNIVERSITY   (Thailand)

Author keywords

Frovatriptan; Migraine; Systematic review; Triptans

Indexed keywords

FROVATRIPTAN; PLACEBO; CARBAZOLE DERIVATIVE; TRYPTAMINE DERIVATIVE;

CARDIOVASCULAR EFFECT; CLINICAL TRIAL; COCHRANE LIBRARY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; EMBASE; FATIGUE; HEADACHE; HIGH RISK PATIENT; HUMAN; MEDLINE; META ANALYSIS; MIGRAINE; NAUSEA; PARESTHESIA; PHONOPHOBIA; PHOTOPHOBIA; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; SINGLE DRUG DOSE; STATISTICAL ANALYSIS; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

CARBAZOLES; DOUBLE-BLIND METHOD; HUMANS; META-ANALYSIS; MIGRAINE DISORDERS; RANDOMIZED CONTROLLED TRIALS; TREATMENT OUTCOME; TRYPTAMINES;

EID: 33644968550     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2005.00677.x     Document Type: Review

References (22)

1. Ferrari MD (1998) Migraine. Lancet, 351, 1043 1051.
2. Snow V, Weiss K, Wall EM, Mottur-Pilson C for the American Academy of Family Physicians and the American College of Physicians-American Society of Internal Medicine (2002) Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Annals of Internal Medicine, 137, 840 849.
3. Krymchantowski AV (2004) Acute treatment of migraine. Breaking the paradigm of monotherapy. BMC Neurology, 4, 4.
4. Silberstein SD (2004) Migraine. Lancet, 363, 381 391.
5. Buchan P, Wade A, Ward C et al. (2002) Frovatriptan: a review of drug-drug interactions. Headache, 2 (Suppl. 2 S63 S73.
6. Buchan P, Keywood C, Wade A, Ward C (2002) Clinical pharmacokinetics of frovatriptan. Headache, 42 (Suppl. 2 A54 S62.
7. Silberstein SD (2002) Pharmacological profile and clinical characteristics of frovatriptan in the acute treatment of migraine: introduction. Headache, 42 (Suppl. 2 S45 S46.
8. Geraud G, Keywood C, Senard JM (2003) Migraine headache recurrence: relationship to clinical, pharmacological, and pharmacokinetic properties of triptans. Headache, 43, 376 388.
9. Ryan R, Geraud G, Goldstein J et al. (2002) Clinical efficacy of frovatriptan: placebo-controlled studies. Headache, 42 (Suppl. 2 S84 S92.
10. Goldstein J, Keywood C (2002) Frovatriptan for the acute treatment of migraine: a dose-finding study. Headache, 42, 41 48.
11. Rapoport A, Ryan R, Goldstein J, Keywood C (2002) Dose range-finding studies with frovatriptan in the acute treatment of migraine. Headache, 42 (Suppl. 2 S74 S83.
12. Geraud G, Spierings ELH, Keywood C (2002) Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache, 42 (Suppl. 2 S93 S99.
13. Belsey JD (2004) Cost effectiveness of oral triptan therapy: a trans-national comparison based on a meta-analysis of randomised controlled trials. Current Medical Research and Opinion, 20, 659 669.
14. Jadad AR, Moore RA, Carroll D et al. (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Controlled Clinical Trials, 17, 1 12.
15. Cook RJ, Sackett DL (1995) The number needed to treat: a clinically useful measure of treatment effect. British Medical Journal, 310, 452 454.
16. Whitehead A, Whitehead J (1991) A general parametric approach to the meta-analysis of randomised clinical trial. Statistics in Medicine, 10, 1665 1677.
17. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Controlled Clinical Trials, 7, 177 188.
18. Elkind AH, Satin LZ, Nila A, Keywood C (2004) Frovatriptan use in migraineurs with or at high risk of coronary artery disease. Headache, 44, 403 410.
19. Cady R, Elkind A, Goldstein J, Keywood C (2004) Randomized, placebo-controlled comparison of early use of frovatriptan in a migraine attack versus dosing after the headache has become moderate or severe. Current Medical Research and Opinion, 20, 1465 1472.
20. Tfelt-Hansen P, Block G, Dahlof C et al. (2000) International Headache Society Clinical Trials Subcommittee. Guidelines for controlled trials of drugs in migraine: second edition. Cephalalgia, 20, 765 786.
21. Rapoport AM, Tepper SJ, Bigal ME, Sheftell FD (2003) The triptan formulations: how to match patients and products. CNS Drugs, 17, 431 437.
22. Michael Cutrer F, Goadsby PJ, Ferrari MD et al. (2004) Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR project). Clinical Therapeutics, 26, 1533 1545.